Opinion of the Transparency Council – nivolumab
At its meeting on 28 October 2024, the Transparency Council adopted opinion No. 175/2024 on covering the reimbursement of medicines containing the active substance nivolumab in terms of indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics